<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Few patients with <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's syndrome have gastrointestinal ulceration </plain></SENT>
<SENT sid="1" pm="."><plain>Such patients are difficult to treat and have a higher mortality </plain></SENT>
<SENT sid="2" pm="."><plain>Faced with refractory symptoms in two patients with intestinal <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's, we used the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor alpha (TNF-alpha) monoclonal antibody infliximab to induce remission </plain></SENT>
<SENT sid="3" pm="."><plain>Both women (one aged 27 years, the other 30 years) presented with orogenital ulceration, pustular <z:e sem="disease" ids="C0015230" disease_type="Disease or Syndrome" abbrv="">rash</z:e>, <z:hpo ids='HP_0002027'>abdominal pain</z:hpo>, <z:e sem="disease" ids="C0151594" disease_type="Disease or Syndrome" abbrv="">bloody diarrhoea</z:e> due to colonic ulceration, <z:hpo ids='HP_0001824'>weight loss</z:hpo>, and <z:hpo ids='HP_0100769'>synovitis</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>One had <z:hpo ids='HP_0004418'>thrombophlebitis</z:hpo>, digital <z:hpo ids='HP_0002633'>vasculitis</z:hpo>, perianal <z:mpath ids='MPATH_70'>fistula</z:mpath>, and paracolic <z:mpath ids='MPATH_612'>abscess</z:mpath>; the other had <z:hpo ids='HP_0000509'>conjunctivitis</z:hpo> and an <z:mpath ids='MPATH_579'>ulcer</z:mpath> in the natal cleft </plain></SENT>
<SENT sid="5" pm="."><plain>Treatment with <z:chebi fb="2" ids="8378">prednisolone</z:chebi>, <z:chebi fb="36" ids="29309">methyl</z:chebi> <z:chebi fb="2" ids="8378">prednisolone</z:chebi>, and thalidomide in one and <z:chebi fb="2" ids="8378">prednisolone</z:chebi>, <z:chebi fb="0" ids="23359">colchicine</z:chebi>, and cyclosporin in the other was ineffective </plain></SENT>
<SENT sid="6" pm="."><plain>After full discussion, infliximab (3 mg/kg, dose reduced because of recent <z:hpo ids='HP_0100806'>sepsis</z:hpo> in one, and 5 mg/kg in the other) was administered </plain></SENT>
<SENT sid="7" pm="."><plain>Within 10 days the <z:mpath ids='MPATH_579'>ulcers</z:mpath> healed, with resolution of <z:e sem="disease" ids="C0151594" disease_type="Disease or Syndrome" abbrv="">bloody diarrhoea</z:e> and <z:hpo ids='HP_0000001'>all</z:hpo> extraintestinal manifestations </plain></SENT>
<SENT sid="8" pm="."><plain>A second infusion of infliximab was necessary eight weeks later in one case, followed by sustained (&gt;15 months) remission on low dose thalidomide </plain></SENT>
<SENT sid="9" pm="."><plain>Remission was initially sustained for 12 months in the other but thalidomide had to be stopped due to intolerance, and a good response to retreatment lasted only 12 weeks without immunosuppression, before a third infusion </plain></SENT>
<SENT sid="10" pm="."><plain>The cause of <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's syndrome is unknown but peripheral blood CD45 gammadelta T cells in <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's produce &gt;50-fold more TNF-alpha than controls when stimulated with <z:chebi fb="0" ids="8116">phorbol</z:chebi> <z:chebi fb="0" ids="30807">myristate</z:chebi> <z:chebi fb="49" ids="30089,47622">acetate</z:chebi> and anti-CD3 </plain></SENT>
<SENT sid="11" pm="."><plain>Infliximab could have a role for inducing remission in <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's syndrome </plain></SENT>
</text></document>